Key result
ADAM9 knockout or neutralization severely impairs encephalomyocarditis virus infection, identifying it as an essential entry factor.
Why the study?
Although EMCV is widely used to study mechanisms of viral disease, little is known about its entry mechanism.
The study identifies the cell-surface protease ADAM9 as an essential entry factor for Encephalomyocarditis Virus (EMCV), providing insight into the viral entry mechanism of a pathogen known to cause myocarditis.
ADAM9 inhibition merits exploration in EMCV myocarditis models; leaves open its viability as a human therapeutic target.
EMCV is an animal pathogen that causes acute viral infections, usually myocarditis or encephalitis. It is thought to circulate mainly among rodents, from which it is occasionally transmitted to other animal species, including humans. EMCV causes fatal outbreaks of myocarditis and encephalitis in pig farms and zoos, making it an important veterinary pathogen. Although EMCV has been widely used as a model to study mechanisms of viral disease in mice, little is known about its entry mechanism. Here, we employ a haploid genetic screen for EMCV host factors and identify an essential role for ADAM9 in EMCV entry.
No takes yet. Share an insight, caveat, or question.
Baggen et al. (2019) studied Encephalomyocarditis Virus (EMCV) infection. ADAM9 knockout or inhibition vs. Wild-type HAP1 cells or untreated controls was evaluated on Viral entry and infection efficiency. Knockout or antibody neutralization of the cell-surface protease ADAM9 severely impaired encephalomyocarditis virus infection, identifying it as an essential factor for viral entry.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: